
Reports Q3 revenue $1.2M, consensus $2.57M. “The third quarter and the weeks since have marked NRx’s transition from a development-stage company to a commercial one,” said Jonathan Javitt, founder, chairman
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| NRXP | NRX Pharmaceuticals | 2.85 | 0.20 | 7.46% |
| Name | Price | % Change | |
|---|---|---|---|
| $2.85 | +7.46% |

Reports Q3 revenue $1.2M, consensus $2.57M. “The third quarter and the weeks since have marked NRx’s transition from a development-stage company to a commercial one,” said Jonathan Javitt, founder, chairman

Nrx Pharmaceuticals, Inc. (NRXP) is scheduled to report 3rd quarter earnings on 11/17/2026, before the market opens. Regarding Q3 estimates, Wall Street analysts expect Nrx Pharmaceuticals, Inc. to post earnings

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, a NDA submission and a psilocybin shipment. EARNINGS: On Monday, Definium

NRx Pharmaceuticals (NRXP) announced that it commenced selling its newly approved preservative-free ketamine providing a guaranteed, U.S.-manufactured supply of a drug listed as in shortage since 2018. Published first on

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on earnings, an extraction completion and analyst views. COMPASS REPORTS EARNINGS: On Tuesday,

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on NRX Pharmaceuticals, with a price target of $45.00. Patrick Trucchio’s Buy rating is based on

NRX Pharmaceuticals ( ($NRXP) ) just unveiled an announcement. On October 30, 2026, the FDA approved NRx Pharmaceuticals’ ANDA for Preservative-Free Ketamine ahead of the November 10 GDUFA goal date.

NRx Pharmaceuticals (NRXP) announced that the FDA has approved the company’s Abbreviated New Drug Application, or ANDA, for Preservative-Free Ketamine. The approval comes ahead of the FDA-announced November 10, approval

NRx Pharmaceuticals (NRXP) stated: “Three days after the New York Times was notified of the false nature of its report, the paper corrected its article to state, ‘In a petition

“The report by the New York Times alleging that NRx Pharmaceuticals (NRXP) submitted no data on the toxicity of Benzethonium Chloride is knowingly false and NRx has demanded a retraction,”
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Apr 1, 2027TBA | $108.60M | $-0.23 | $2.22M | 0.05 | -4.53 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.